The earnings call discussed progress in Ovaprene study enrollment and upcoming milestones. Interim review expected by end of Q2 2025 will focus on safety in open-label study. Operational progress for Sildenafil Cream phase three involves defining endpoints and aligning with FDA on efficacy and safety expectations.